AEs and ADRs occurred in every 17 sufferers (Desk 4)
AEs and ADRs occurred in every 17 sufferers (Desk 4). 11.7 (1.8C42.3) a few months, respectively. The 3-season overall survival price was 80.4% (95% confidence period = 50.6C93.2%). Nivolumab was…